MYC and hepatocellular carcinoma: Anthony W. Tolcher reported that DCR-MYC is well-tolerated and shows encouraging clinical and metabolic effects across a range of doses.596 In a phase Ib/II clinical trial (NCT02314052), DCR-MYC was evaluated in patients with advanced HCC to assess its safety and tolerability.